Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Baxter

Last Updated: September 27, 2022

Details for Patent: 9,206,135


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,206,135 protect, and when does it expire?

Patent 9,206,135 protects APTIOM and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 9,206,135
Title:Asymmetric catalytic reduction of oxcarbazepine
Abstract: A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00001## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R.sup.1 can be the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR.sup.3R.sup.4R.sup.5 and formic acid, [R.sup.3R.sup.4R.sup.5NH][OOCH] and optionally formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.
Inventor(s): Learmonth; David Alexander (Alfena, PT), Grasa; Gabriela Alexandra (Mantua, NJ), Zanotti-Gerosa; Antonio (Cambridge, GB)
Assignee: Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:13/651,844
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,206,135
Patent Claim Types:
see list of patent claims
Compound; Process; Use;

Drugs Protected by US Patent 9,206,135

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,206,135

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0515690.6Jul 29, 2005

International Family Members for US Patent 9,206,135

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055917 See Plans and Pricing
Austria 520665 See Plans and Pricing
Australia 2006273874 See Plans and Pricing
Brazil PI0615970 See Plans and Pricing
Canada 2616984 See Plans and Pricing
China 101277937 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
Dow
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.